BR112018002196A8 - formulação anti-ifnar1 estável - Google Patents
formulação anti-ifnar1 estávelInfo
- Publication number
- BR112018002196A8 BR112018002196A8 BR112018002196A BR112018002196A BR112018002196A8 BR 112018002196 A8 BR112018002196 A8 BR 112018002196A8 BR 112018002196 A BR112018002196 A BR 112018002196A BR 112018002196 A BR112018002196 A BR 112018002196A BR 112018002196 A8 BR112018002196 A8 BR 112018002196A8
- Authority
- BR
- Brazil
- Prior art keywords
- formulation
- antibody
- stable
- ifnar1
- infar1
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 102000006992 Interferon-alpha Human genes 0.000 abstract 1
- 108010047761 Interferon-alpha Proteins 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000012537 formulation buffer Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
Abstract
a presente invenção refere-se a uma formulação de anticorpo estável e de baixa viscosidade, em que a formulação compreende uma elevada concentração de um anticorpo anti-infar1. em algumas modalidades, a invenção refere-se, em geral, com uma formulação de anticorpo estável compreendendo cerca de 100 mg/ml a cerca de 200 mg/ml de um anticorpo ou um fragmento do mesmo que se liga especificamente ao interferão alfa 1 humano (infar1); cerca de 20 mm a cerca de 80 mm de uma lisina ou um sal do mesmo; cerca de 0,02% a cerca de 0,06% de um tensoativo; um excipiente não carregado; e um tampão de formulação. em algumas modalidades, a invenção diz respeito a um recipiente, uma forma de dosagem e/ou um kit. em algumas modalidades, a invenção diz respeito a um método de preparação e uso da formulação de anticorpo estável.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562207164P | 2015-08-19 | 2015-08-19 | |
| US62/207,164 | 2015-08-19 | ||
| PCT/US2016/047506 WO2017031288A1 (en) | 2015-08-19 | 2016-08-18 | Stable anti-ifnar1 formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112018002196A2 BR112018002196A2 (pt) | 2019-04-30 |
| BR112018002196A8 true BR112018002196A8 (pt) | 2021-05-04 |
Family
ID=58052002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018002196A BR112018002196A8 (pt) | 2015-08-19 | 2016-08-18 | formulação anti-ifnar1 estável |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US10125195B2 (pt) |
| EP (3) | EP4233892A3 (pt) |
| JP (4) | JP6720293B2 (pt) |
| KR (4) | KR20220127378A (pt) |
| CN (1) | CN107921109A (pt) |
| AU (3) | AU2016308262C1 (pt) |
| BR (1) | BR112018002196A8 (pt) |
| CA (1) | CA2995222C (pt) |
| CY (2) | CY1123657T1 (pt) |
| DK (2) | DK3337502T3 (pt) |
| ES (2) | ES2947488T3 (pt) |
| FI (1) | FI3769781T3 (pt) |
| HR (2) | HRP20230463T1 (pt) |
| HU (2) | HUE061985T2 (pt) |
| IL (1) | IL257279B2 (pt) |
| LT (2) | LT3769781T (pt) |
| PL (2) | PL3769781T3 (pt) |
| PT (2) | PT3337502T (pt) |
| RS (2) | RS64263B1 (pt) |
| RU (1) | RU2731737C2 (pt) |
| SG (1) | SG10202106970XA (pt) |
| SI (2) | SI3769781T1 (pt) |
| SM (2) | SMT202000483T1 (pt) |
| WO (1) | WO2017031288A1 (pt) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS64263B1 (sr) | 2015-08-19 | 2023-07-31 | Astrazeneca Ab | Stabilna anti-ifnar1 formulacija |
| GB201719447D0 (en) | 2017-11-23 | 2018-01-10 | Ucb Biopharma Sprl | Pharmaceutical composition |
| US20200061015A1 (en) * | 2018-08-23 | 2020-02-27 | Janssen Biotech, Inc. | Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| CN110179746A (zh) * | 2019-05-17 | 2019-08-30 | 通化东宝生物科技有限公司 | 一种稳定的苏金单抗注射剂及其制备方法 |
| TW202133877A (zh) * | 2019-11-11 | 2021-09-16 | 瑞典商阿斯特捷利康公司 | 全身性紅斑狼瘡中之ｉ型干擾素抑制 |
| EP4566667A2 (en) | 2020-05-29 | 2025-06-11 | AstraZeneca AB | Treatment of cardiometabolic disease with inhibitors of type i interferon signalling |
| US20230287092A1 (en) | 2020-06-25 | 2023-09-14 | Medimmune Limited | Prevention of axonal damage using antibody binding to amyloid beta 1-42 |
| TW202237647A (zh) | 2020-10-08 | 2022-10-01 | 瑞典商阿斯特捷利康公司 | 狼瘡發作之治療 |
| AU2022260531B2 (en) | 2021-04-23 | 2024-03-07 | Astrazeneca Ab | Anti-ifnar1 dosing regime for subcutaneous injection |
| CN117222430A (zh) | 2021-04-23 | 2023-12-12 | 阿斯利康(瑞典)有限公司 | 皮肤红斑狼疮的治疗 |
| DK4192882T3 (da) | 2021-04-23 | 2025-03-10 | Astrazeneca Ab | Behandling af lupus nephritis med anti-type i inf-receptor-antistof anifrolumab |
| CN117157099A (zh) * | 2021-04-23 | 2023-12-01 | 阿斯利康(瑞典)有限公司 | 用于皮下注射的抗ifnar1给药方案 |
| IL308128A (en) | 2021-05-12 | 2023-12-01 | Astrazeneca Ab | Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythematosus patients |
| WO2023284073A1 (zh) * | 2021-07-13 | 2023-01-19 | 江苏荃信生物医药股份有限公司 | 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法、抗人ifnar1单克隆抗体浓缩溶液的制备方法以及液体制剂 |
| CN113527490B (zh) * | 2021-07-13 | 2022-03-01 | 江苏荃信生物医药股份有限公司 | 一种抗人ifnar1单克隆抗体浓缩溶液的制备方法 |
| CN113521276B (zh) * | 2021-07-13 | 2022-04-12 | 江苏荃信生物医药股份有限公司 | 包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂 |
| AU2022317215A1 (en) | 2021-07-27 | 2024-02-29 | Astrazeneca Ab | Treatment of lupus |
| IL311691A (en) | 2021-10-04 | 2024-05-01 | Astrazeneca Ab | Treatment of lupus |
| CA3234358A1 (en) * | 2021-10-29 | 2023-05-04 | Intas Pharmaceuticals Ltd. | Stable lyophilized formulation of an anti-.alpha.4.beta.7 antibody |
| TW202337497A (zh) * | 2022-02-18 | 2023-10-01 | 中國大陸商重慶明道浩悅生物科技有限公司 | 鼻內調配物及抗sars-cov-2棘蛋白抗體 |
| WO2024009205A1 (en) * | 2022-07-06 | 2024-01-11 | Intas Pharmaceuticals Ltd. | STABLE LIQUID FORMULATION OF AN ANTI-Α4ß7 ANTIBODY |
| TW202430212A (zh) | 2022-10-13 | 2024-08-01 | 瑞典商阿斯特捷利康公司 | 狼瘡之治療 |
| WO2024241156A1 (en) | 2023-05-19 | 2024-11-28 | Astrazeneca Ab | Treatment of lupus |
| WO2025022280A1 (en) | 2023-07-21 | 2025-01-30 | Astrazeneca Ab | Treatment of neurodegenerative diseases |
| GB202315831D0 (en) | 2023-10-16 | 2023-11-29 | Astrazeneca Ab | Treatment of skin disease |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6713609B1 (en) * | 1996-07-16 | 2004-03-30 | Genentech, Inc. | Monoclonal antibodies to type I interferon receptor |
| KR20130012258A (ko) | 2004-06-21 | 2013-02-01 | 메다렉스, 인코포레이티드 | 인터페론 알파 수용체 1 항체 및 그의 용도 |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| RU2009126420A (ru) * | 2006-12-11 | 2011-01-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Парентеральная лекарственная форма антитела к абета |
| JP5513380B2 (ja) * | 2007-06-25 | 2014-06-04 | アムジエン・インコーポレーテツド | 肝細胞増殖因子に対する特異的結合剤の組成物 |
| EP2225275A4 (en) * | 2007-11-28 | 2013-04-03 | Medimmune Llc | PROTEIN FORMULATION |
| ES2581917T3 (es) * | 2008-02-08 | 2016-09-08 | Medimmune, Llc | Anticuerpos anti-IFNAR1 con afinidad de ligando de Fc reducida |
| ES2719496T3 (es) | 2008-11-12 | 2019-07-10 | Medimmune Llc | Formulación de anticuerpo |
| US20110152188A1 (en) * | 2009-12-23 | 2011-06-23 | Hanns-Christian Mahler | Pharmaceutical compositions of igf/i proteins |
| US20110223208A1 (en) * | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| MY171920A (en) * | 2011-10-12 | 2019-11-07 | Ascendis Pharma Ophthalmology Div A/S | Prevention and treatment of ocular conditions |
| EP2771033A4 (en) | 2011-10-28 | 2016-02-17 | Integritybio Inc | PROTEIN FORMULATIONS CONTAINING AMINO ACIDS |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| JP2015536934A (ja) | 2012-10-25 | 2015-12-24 | メディミューン，エルエルシー | 安定した低粘度の抗体製剤 |
| US10259842B2 (en) | 2013-05-15 | 2019-04-16 | Medimmune, Llc | Purification of recombinantly produced polypeptides |
| IL312865B2 (en) * | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-reducing agents |
| WO2015063180A1 (en) * | 2013-10-29 | 2015-05-07 | Novozymes Biopharma Dk A/S | Antibody composition |
| WO2016034648A1 (en) | 2014-09-03 | 2016-03-10 | Medimmune Limited | Stable anti-il-4r-alpha antibody formulation |
| EP3240571A4 (en) | 2014-12-31 | 2018-06-13 | NovelMed Therapeutics, Inc. | Formulation of aglycosylated therapeutic antibodies |
| RS64263B1 (sr) | 2015-08-19 | 2023-07-31 | Astrazeneca Ab | Stabilna anti-ifnar1 formulacija |
-
2016
- 2016-08-18 RS RS20230447A patent/RS64263B1/sr unknown
- 2016-08-18 IL IL257279A patent/IL257279B2/en unknown
- 2016-08-18 US US15/240,224 patent/US10125195B2/en active Active
- 2016-08-18 CN CN201680047012.7A patent/CN107921109A/zh active Pending
- 2016-08-18 DK DK16837818.0T patent/DK3337502T3/da active
- 2016-08-18 KR KR1020227031079A patent/KR20220127378A/ko not_active Ceased
- 2016-08-18 FI FIEP20174805.0T patent/FI3769781T3/fi active
- 2016-08-18 HU HUE20174805A patent/HUE061985T2/hu unknown
- 2016-08-18 SI SI201631699T patent/SI3769781T1/sl unknown
- 2016-08-18 HR HRP20230463TT patent/HRP20230463T1/hr unknown
- 2016-08-18 SM SM20200483T patent/SMT202000483T1/it unknown
- 2016-08-18 KR KR1020187007314A patent/KR102168005B1/ko active Active
- 2016-08-18 KR KR1020247016705A patent/KR20240090616A/ko active Pending
- 2016-08-18 KR KR1020207029325A patent/KR102669174B1/ko active Active
- 2016-08-18 PL PL20174805.0T patent/PL3769781T3/pl unknown
- 2016-08-18 RU RU2018107725A patent/RU2731737C2/ru active
- 2016-08-18 SI SI201630900T patent/SI3337502T1/sl unknown
- 2016-08-18 EP EP23160045.3A patent/EP4233892A3/en active Pending
- 2016-08-18 EP EP20174805.0A patent/EP3769781B1/en active Active
- 2016-08-18 PL PL16837818T patent/PL3337502T3/pl unknown
- 2016-08-18 SG SG10202106970XA patent/SG10202106970XA/en unknown
- 2016-08-18 PT PT168378180T patent/PT3337502T/pt unknown
- 2016-08-18 EP EP16837818.0A patent/EP3337502B1/en active Active
- 2016-08-18 DK DK20174805.0T patent/DK3769781T5/da active
- 2016-08-18 ES ES20174805T patent/ES2947488T3/es active Active
- 2016-08-18 PT PT201748050T patent/PT3769781T/pt unknown
- 2016-08-18 AU AU2016308262A patent/AU2016308262C1/en active Active
- 2016-08-18 HR HRP20201297TT patent/HRP20201297T1/hr unknown
- 2016-08-18 JP JP2018508149A patent/JP6720293B2/ja active Active
- 2016-08-18 RS RS20201103A patent/RS60773B1/sr unknown
- 2016-08-18 ES ES16837818T patent/ES2818229T3/es active Active
- 2016-08-18 CA CA2995222A patent/CA2995222C/en active Active
- 2016-08-18 WO PCT/US2016/047506 patent/WO2017031288A1/en active Application Filing
- 2016-08-18 BR BR112018002196A patent/BR112018002196A8/pt active Search and Examination
- 2016-08-18 SM SM20230176T patent/SMT202300176T1/it unknown
- 2016-08-18 LT LTEP20174805.0T patent/LT3769781T/lt unknown
- 2016-08-18 HU HUE16837818A patent/HUE051862T2/hu unknown
- 2016-08-18 LT LTEP16837818.0T patent/LT3337502T/lt unknown
-
2020
- 2020-05-21 AU AU2020203306A patent/AU2020203306C1/en active Active
- 2020-06-17 JP JP2020104494A patent/JP7035119B2/ja active Active
- 2020-09-11 CY CY20201100860T patent/CY1123657T1/el unknown
-
2021
- 2021-10-26 AU AU2021257915A patent/AU2021257915A1/en not_active Abandoned
-
2022
- 2022-03-02 JP JP2022031581A patent/JP2022066345A/ja active Pending
-
2023
- 2023-06-20 CY CY20231100289T patent/CY1126062T1/el unknown
-
2024
- 2024-08-22 JP JP2024140769A patent/JP2024161043A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018002196A8 (pt) | formulação anti-ifnar1 estável | |
| BR112017003419A2 (pt) | formulação de anticorpo anti-il-4r-alfa estável | |
| NZ743964A (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| AR130402A2 (es) | Formulaciones de anticuerpos anti-pdl1 | |
| MX2019010282A (es) | Formulacion de anticuerpos monoclonales. | |
| AR127361A2 (es) | Composición farmacéutica de partículas de lipoplejos y arn, composición acuosa y método de preparación | |
| EA201792273A1 (ru) | Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела | |
| CL2019002478A1 (es) | Formulación de anticuerpo monoclonal anti-vrs. | |
| AR124676A2 (es) | Formulación farmacéutica que comprende una droga biofarmacéutica | |
| BR112014021325A2 (pt) | Formulação farmacêutica líquida e formulação liofilizada | |
| CU20190015A7 (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden | |
| SG11201807765PA (en) | Antibody-containing preparation | |
| NZ711567A (en) | Antibody formulations | |
| BR112021017890A2 (pt) | Composição líquida compreendendo um anticorpo do receptor alfa de interleucina-4 humana | |
| BR112017016636A2 (pt) | formulação líquida estável para anticorpos monoclonais | |
| AR080795A1 (es) | Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6) | |
| BR112018075140A2 (pt) | composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8 | |
| MX2015015152A (es) | Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13. | |
| EA202090683A2 (ru) | Способы и композиции для лечения рака | |
| EA201991447A1 (ru) | Снижение вязкости фармацевтических составов | |
| BR112016015660A2 (pt) | formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg) | |
| PE20191242A1 (es) | Formulaciones de anticuerpo y metodos | |
| MX2017003121A (es) | Formulaciones de anticuerpos. | |
| BR112017012406A2 (pt) | formulação com relação fixa de insulina glargina/lixisenatida | |
| BR112016028227A2 (pt) | método para redução de imunogenicidade de proteína e peptídeo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |